Top

Published in:

01-01-2008 | Original Article

Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation

Authors: Atsuko Fujihara, Masayuki Kurooka, Tsuneharu Miki, Yasufumi Kaneda

Published in: Cancer Immunology, Immunotherapy | Issue 1/2008

Abstract

We have already demonstrated that inactivated, replication-defective Sendai virus particles (HVJ-E) have a powerful antitumor effect by both the generation of tumor-specific cytotoxic T cells and inhibition of regulatory T cell activity. Here, we report that HVJ-E also has an antitumor effect through non-T cell immunity. Microarray analysis revealed that direct injection of HVJ-E induced the expression of CXCL10 in established Renca tumors. CXCL10 was secreted by dendritic cells in the tumors after HVJ-E injection. Quantitative real-time RT-PCR and immunohistochemistry revealed that CXCR3+ cells (predominantly NK cells) infiltrated the HVJ-E-injected tumors. Moreover, HVJ-E injection caused systemic activation of NK cells and enhanced their cytotoxity against tumor cells. In an in vivo experiment, approximately 50% of tumors were eradicated by HVJ-E injection, and this activity of HVJ-E against Renca tumors was largely abolished by NK cell depletion using anti-asialo GM1 antibody. Since HVJ-E injection induced systemic antitumor immunity by enhancing or correcting the chemokine-chemokine receptor axis, it might be a potential new therapy for cancer.

Asada T (1974) Treatment of human cancer with mumps virus. Cancer 34:1907–1928PubMedCrossRef

Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4:540–550PubMedCrossRef

Barber GN (2005) VSV-tumor selective replication and protein translation. Oncogene 24:7710–9PubMedCrossRef

Bluming AZ, Ziegler JL (1971) Regression of Burkitt’s lymphoma in association with measles infection. Lancet 2:105–106PubMedCrossRef

Cassel WA, Garrett RE (1965) Newcastle disease virus as an antineoplastic agent. Cancer 18:863–868PubMedCrossRef

Colonna M, Krug A, Cella M (2002) Interferon-producing cells: on the front line in immune responses against pathogens. Curr Opin Immunol 14:373–379PubMedCrossRef

Davis JJ, Fang B (2005) Oncolytic virotherapy for cancer treatment: challenges and solutions. J Gene Med 7:1380–1389PubMedCrossRef

Diebold SS, Montoya M, Unger H, Alexopoulou L, Roy P, Haswell LE, Al-Shamkhani A, Flavell R, Borrow P, Reise Sousa C (2003) Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 424:324–328PubMedCrossRef

Errington F, Bateman A, Kottke T, Thompson J, Harrington K, Merrick A, Hatfield P, Selby P, Vile R, Melcher A (2006) Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. Clin Cancer Res 12:1333–1341PubMedCrossRef

10.

Fan Z, Yu P, Wang Y, Wang Y, Fu ML, Liu W, Sun Y, Fu YX (2006) NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood 107:1342–1351PubMedCrossRef

11.

Farber JM (1997) Mig and IP-10: CXC chemokines that target lymphocytes

12.

Gabrilovich DI (2006) INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. Expert Opin Biol Ther 6:823–832PubMedCrossRef

13.

Hann B, Balmain A (2003) Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants. J Virol 77:11588–11595PubMedCrossRef

14.

Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3:639–645PubMedCrossRef

15.

Horowitz J (1999) Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications. Curr Opin Mol Ther 1:500–509PubMed

16.

Hoshino K, Kaisho T, Iwabe T, Takeuchi O, Akira S (2002) Differential involvement of IFN-β in Toll-like receptor-stimulated dendritic cell activation. Int Immunol 14:1225–1231PubMedCrossRef

17.

Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176:1693–1702PubMedCrossRef

18.

Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y (2005) Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 7:1044–1052PubMedCrossRef

19.

Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987–985PubMedCrossRef

20.

Jia W, Zhou Q (2005) Viral vectors for cancer gene therapy: viral dissemination and tumor targeting. Curr Gene Ther 5:133–142PubMed

21.

Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, Nakamura H, Morishita R, Kotani H (2002) Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 6:219–226PubMedCrossRef

22.

Kaneda Y, Saeki Y, Morishita R (1999) Gene therapy using HVJ-liposomes: the best of both worlds? Mol Med Today 5:298–303PubMedCrossRef

23.

Kaneda Y, Yamamoto S, Nakajima T (2005) Development of HVJ envelope vector and its application to gene therapy. Adv Genet 53:307–332PubMed

24.

Kurihara T, Brough DE, Kovesdi I, Kufe DW (2000) Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 106:763–771PubMedCrossRef

25.

Kurooka M, Kaneda Y (2007) Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 67:227–236PubMedCrossRef

26.

Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B (1996) Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184:963–969PubMedCrossRef

27.

Lopez CB, Garcia-Sastre A, Williams BR, Moran TM (2003) Type I interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negative-strand RNA viruses. J Infect Dis 187:1126–1136PubMedCrossRef

28.

Lopez CB, Moltedo B, Alexopoulou L, Bonifaz L, Flavell RA, Moran TM (2004) TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses. J Immunol 173:6882–6889PubMed

29.

Luster AD, Leder P (1993) IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 178:1057–1065PubMedCrossRef

30.

McCormick F (2003) Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther 2:S157–S160PubMed

31.

Mima H, Yamamoto S, Ito M, Tomoshige R, Tabata Y, Tamai K, Kaneda Y (2006) Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. Mol Cancer Ther 5:1021–1028PubMedCrossRef

32.

Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, Scaltrini F, Pasquali C, Calori G, Pessi F, Sperti C (2003) The CC Chemokine MCP-1/CCL2 in Pancreatic Cancer progression regulation of expression and potential mechanisms of antimalignant activity 1. AACR

33.

Nemunaitis J, Cunningham C, Tong AW, Post L, Netto G, Paulson AS, Rich D, Blackburn A, Sands B, Gibson B, Randlev B, Freeman S (2003) Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther 10:341–52PubMedCrossRef

34.

Nishimura F, Dusak JE, Eguchi J, Zhu X, Gambotto A, Storkus WJ, Okada H (2006) Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. AACR

35.

Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW (2004) Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 101:11099–11104PubMedCrossRef

36.

Ohmori Y (1995) The interferon-stimulated response element and a kappa B site mediate synergistic induction of murine IP-10 gene transcription by IFN-gamma and TNF-alpha. J Immunol 154:5235–5244PubMed

37.

Okada Y (1993) Sendai virus-induced cell fusion. Methods Enzymol 221:18–41PubMed

38.

Oshima K, Shimamura M, Mizuno S, Tamai K, Doi K, Morishita R, Nakamura T, Kubo T, Kaneda Y (2004) Intrathecal injection of HVJ-E containing HGF gene to cerebrospinal fluid can prevent and ameliorate hearing impairment in rats. Faseb J 18:212–4PubMed

39.

Pan J, Burdick MD, Belperio JA, Xue YY, Gerard C, Sharma S, Dubinett SM, Strieter RM (2006) CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol 176:1456–1464PubMed

40.

Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O’Neil JD, Groene WS, Roberts MS, Rabin H, Bamat MK, Lorence RM (2002) Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20:2251–2266PubMedCrossRef

41.

Petersson M, Charo J, Salazar-Onfray F, Noffz G, Mohaupt M, Qin Z, Klein G, Blankenstein T, Kiessling R (1998) Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1 1. J Immunol 161:2099–2105PubMed

42.

Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B, Mackay CR (1998) The Chemokine Receptors CXCR3 and CCR5 Mark Subsets of T Cells Associated with Certain Inflammatory Reactions. Am Soc Clin Investig 104(4):746–754CrossRef

43.

Robbins PD, Tahara H, Ghivizzani SC (1998) Viral vectors for gene therapy. Trends Biotechnol 16:35–40PubMedCrossRef

44.

Roth JA (2006) Adenovirus p53 gene therapy. Expert Opin Biol Ther 6:55–61PubMedCrossRef

45.

Russell SJ (2002) RNA viruses as virotherapy agents. Cancer Gene Ther 9:961–966PubMedCrossRef

46.

Sgadari C, Angiolillo AL, Cherney BW, Pike SE, Farber JM, Koniaris LG, Vanguri P, Burd PR, Sheikh N, Gupta G, Teruya-Feldstein J, Tosato G (1996) Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 93:13791–13796PubMedCrossRef

47.

Shurin MR, Shurin GV, Lokshin A, Yurkovetsky ZR, Gutkin DW, Chatta G, Zhong H, Han B, Ferris RL (2006) Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 25(3):333–356PubMedCrossRef

48.

Sun Y, Finger C, Alvarez-Vallina L, Cichutek K, Buchholz CJ (2005) Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth. Cancer Gene Ther 12:900–912PubMedCrossRef

49.

Tang J, Murtadha M, Schnell M, Eisenlohr LC, Hooper J, Flomenberg P (2006) Human T-cell responses to vaccinia virus envelope proteins. J Virol 80:10010–10020PubMedCrossRef

50.

Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA (1998) The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 161:927–932PubMed

51.

Taub DD (1993) Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 177:1809–1814PubMedCrossRef

52.

Terme M, Tomasello E, Maruyama K, Crepineau F, Chaput N, Flament C, Marolleau JP, Angevin E, Wagner EF, Salomon B, Lemonnier FA, Wakasugi H, Colonna M, Vivier E, Zitvogel L (2004) IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules. J Immunol 172:5957–5966PubMed

53.

Trifilo MJ, Montalto-Morrison C, Stiles LN, Hurst KR, Hardison JL, Manning JE, Masters PS, Lane TE (2004) CXC Chemokine ligand 10 controls viral infection in the central nervous system: evidence for a role in innate immune response through recruitment and activation of natural killer cells. J Virol 78:585PubMedCrossRef

54.

Van de Broek I, Leleu X, Schots R, Facon T, Vanderkerken K, Van Camp B, Van Riet I (2006) Clinical significance of chemokine receptor(CCR 1, CCR 2 and CXCR 4) expression in human myeloma cells: the association with disease activity and survival. Haematologica(Roma) 91:200–206

55.

Vanguri P (1994) IFN and virus-inducible expression of an immediate early gene, crg-2/IP-10, and a delayed gene, IA alpha in astrocytes and microglia. J Immunol 152:1411–8PubMed

56.

Vanguri P, Farber JM (1990) Identification of CRG-2. An interferon-inducible mRNA predicted to encode a murine monokine. J Biol Chem 265:15049–15057PubMed

57.

Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E (2005) Natural-killer cells and dendritic cells: “l’union fait la force”. Blood 106:2252–2258PubMedCrossRef

58.

Wilson DR (2002) Viral-mediated gene transfer for cancer treatment. Curr Pharm Biotechnol 3:151–164PubMedCrossRef

59.

Wirth T, Zender L, Schulte B, Mundt B, Plentz R, Rudolph KL, Manns M, Kubicka S, Kuhnel F (2003) A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 63:3181–3188PubMed

60.

Yokoyama WM, Seaman WE (1993) THE Ly-49 AND NKR-P1 gene families encoding Lectin-like receptors on natural killer cells: the NK gene complex. Annu Rev lmmunol 11:613–635

61.

Yonemitsu Y, Kitson C, Ferrari S, Farley R, Griesenbach U, Judd D, Steel R, Scheid P, Zhu J, Jeffery PK, Kato A, Hasan MK, Nagai Y, Masaki I, Fukumura M, Hasegawa M, Geddes DM, Alton EW (2000) Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 18:970–973PubMedCrossRef

62.

Young LS, Searle PF, Onion D, Mautner V (2006) Viral gene therapy strategies: from basic science to clinical application. J Pathol 208:299–318PubMedCrossRef

Title: Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation
Authors: Atsuko Fujihara
Masayuki Kurooka
Tsuneharu Miki
Yasufumi Kaneda
Publication date: 01-01-2008
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 1/2008
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-007-0351-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

HLA-DPB1 supertype-associated protection from childhood leukaemia: relationship to leukaemia karyotype and implications for prevention

EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells

Preferential migration of regulatory T cells mediated by gliomasecreted chemokines can be blocked with chemotherapy

A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells

Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+ T cells against tumors

Ethnic differences in cytokine gene polymorphisms: potential implications for cancer development

Keynote webinar | Spotlight on antibody–drug conjugates in cancer